Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
Sponsored by Revance Therapeutics, Inc.
About this trial
Last updated 11 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 12 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Moderate to severe crow's feet lines
- Female or male, 18 to 65 years of age and in good general health
- Women of childbearing potential (WOCBP) must agree to use an effective method of birth control during the course of the study
Exclusion Criteria
- Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A
- Muscle weakness or paralysis, particularly in the area receiving study treatment
- Active skin disease or irritation at the treatment area
- Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart
- Treatment with botulinum toxin type A for crow's feet lines in the last 6 months